Core Insights - The company has reported impressive results from Phase Ib clinical studies of its long-acting helicase-primase inhibitor candidates, ABI-1179 and ABI-5366, for treating recurrent genital herpes [3]. Group 1: Clinical Study Results - Both ABI-1179 and ABI-5366 met or exceeded all key objectives of the study, indicating a significant advancement in treatment options for individuals with recurrent genital herpes [3]. - The data suggests a potential path to a best-in-class therapy, particularly in terms of dosing interval and improved efficacy compared to currently approved agents [3].